Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-06-18 23:00 |
Biophytis announces new convertible bond financing for up to €32 million with A…
|
English | 238.3 KB | ||
| 2021-06-18 23:00 |
Biophytis annonce un nouveau financement en obligations convertibles pouvant at…
|
French | 235.4 KB | ||
| 2021-05-12 08:00 |
Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study…
|
English | 148.1 KB | ||
| 2021-05-12 08:00 |
Biophytis a terminé le Recrutement des 155 Patients de l’étude COVA de phase 2-…
|
French | 142.4 KB | ||
| 2021-05-11 08:00 |
Results of the Combined General Meeting on May 10, 2021 All ordinary and extra…
|
English | 187.5 KB | ||
| 2021-05-11 08:00 |
Résultats de l’Assemblée Générale Mixte du 10 mai 2021 Adoption de l’ensemble d…
|
French | 189.6 KB | ||
| 2021-04-30 08:00 |
L’Assemblée générale mixte de Biophytis aura lieu sur seconde convocation le 10…
|
French | 134.5 KB | ||
| 2021-04-30 08:00 |
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 witho…
|
English | 132.0 KB | ||
| 2021-04-29 08:00 |
Biophytis Receives €980,000 DeepTech Funding from BPI France for the developmen…
|
English | 133.0 KB | ||
| 2021-04-29 08:00 |
Biophytis reçoit un financement de 980 000 € du plan Deeptech de Bpifrance pour…
|
French | 136.1 KB | ||
| 2021-04-27 08:00 |
Biophytis - Convening of Another Combined General Meeting at a Later Date
|
English | 121.9 KB | ||
| 2021-04-27 08:00 |
Biophytis - Convocation à une seconde Assemblée générale mixte à une date ultér…
|
French | 127.3 KB | ||
| 2021-04-26 08:00 |
Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of it…
|
English | 150.3 KB | ||
| 2021-04-26 08:00 |
Biophytis fait le Point sur ses Perspectives Opérationnelles concernant Sarcone…
|
French | 154.0 KB | ||
| 2021-04-13 23:00 |
Biophytis Identifies False Report Regarding COVA study
|
English | 108.6 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
